Who is Siam Bioscience Group?
Siam Bioscience group has been established since 2009, consisted of 2 major companies–Siam Bioscience Co.,Ltd. and Apexcela Co.,Ltd. Siam Bioscience Group, established in 2009, believed that accessibility to high quality and effective healthcare products is the basic rights for all.
What kind of company is SK Bioscience Co Ltd?
Surveillance The Tape Businessweek The Pay Check Prognosis Travel Genius Works for Me Trillions All Podcasts… All Radio Shows… Quick Links Stocks Currencies Commodities Rates & Bonds Sectors Watchlist Recently Viewed Companies SK Bioscience Co Ltd SK Bioscience Co.,Ltd. operates biopharmaceutical businesses.
What is the main business of Siam Commercial Bank?
Siam Commercial Bank Public Company Limited provides a full range of banking and financial services. The Bank offers corporate and personal lending, retail and wholesale banking, international trade financing, and investment banking services to its customers throughout Thailand.
See more
Sinovac Amends Shareholder Rights Plan
SINOVAC Reports Unaudited First Half of 2021 Financial Results
BEIJING, February 22, 2022--Sinovac Biotech Ltd. ("Sinovac" or the "Company") (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, today announced that its board of directors has amended its shareholder rights plan. The amendment extends the expiration date of the plan from February 22, 2022 to February 22, 2023.
Why AstraZeneca Could Be a Sound Long-Term Bet
BEIJING, December 30, 2021--Sinovac Biotech Ltd. (NASDAQ: SVA) ("SINOVAC" or the "Company"), a leading provider of biopharmaceutical products in China, announced today its unaudited financial results for the six months ended June 30, 2021.
AstraZeneca Gaps Higher After Touting 'Historic' And Unexpected Win In Breast Cancer
It's the big pharma company that "has the best stuff with the least warts,” says T. Rowe Price’s Ziad Bakri.
Roche And AstraZeneca Settle Ultomiris Patent Lawsuit
AstraZeneca popped to a three-month high after the company touted a previously unheard-of result for its breast cancer treatment, Enhertu.
New global trial to review impact of reduced COVID-19 booster shots, as England drops all restrictions
Roche Holdings AG (OTC: RHHBY) has decided to close out a patent infringement lawsuit against AstraZeneca plc (NASDAQ: AZN), centering around the latter's newly acquired rare disease drug Ultomiris for a rare blood disorder.
AstraZeneca Stock Is Rising. Data From a Breast-Cancer Trial Were Positive
A global clinical trial was launched Tuesday to investigate the impact of reduced COVID-19 booster shots, as opposed to full ones, as a way to improve access to vaccines for those parts of the world that still have low vaccination rates.
AstraZeneca (AZN) Enhertu Effective in HER2-Low Breast Cancer
American depositary receipts of AstraZeneca were higher after the drug giant saw positive results from a trial of its cancer drug Enhertu in patients with a difficult-to-treat form of breast cancer.
AstraZeneca's Stock Gain After Enhertu Meets Primary Endpoint In HER2-Low Breast Cancer Setting
AstraZeneca's (AZN) DESTINY-Breast04 is the first-ever phase III study of a HER2-directed therapy to show a statistically significant and clinically meaningful survival benefit in patients with HER2-low metastatic breast cancer.
.jpg)